Novo Nordisk and Valo Health Expand AI-Driven Collaboration to Develop Novel Treatments for Obesity, Type 2 Diabetes, and Cardiovascular Disease
Expanded Collaboration:
Novo Nordisk and Valo Health have expanded their partnership to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease using Valo’s extensive human dataset and AI-powered computation13.
Increased Scope:
The collaboration now includes up to 20 drug programs, an addition of 9 new programs, with potential milestone payments totaling approximately $4.6 billion, plus R&D funding and potential royalty payments12.
Initial Progress:
The partnership has already led to the identification of several novel targets for cardiometabolic drug programs and is actively working on multiple small molecule preclinical drug discovery programs1.
AI-Driven Approach:
The collaboration leverages Valo’s Opal Computational Platform, which uses AI to identify and validate novel drug targets using real-world data and human models1.
Strategic Partnership:
The expanded agreement allows for a deeper partnership between the two companies, spanning the entire drug discovery continuum, with a focus on deriving novel insights from human genetic and longitudinal patient data1.
Sources:
1. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915085
2. https://endpts.com/novo-expands-pact-with-flagships-valo-to-include-obesity-diabetes-for-190m-near-term/